Progress and prospects in research and clinical practice of hormone receptor-positive, HER-2-negative breast cancer with BRCA1/2 mutations
Abstract Breast cancer (BC) is a heterogeneous disease that is the most common cancer in women worldwide. However, precise subtyping and corresponding treatments have improved patient outcomes. Hormone receptor (HR)-positive, human epidermal growth factor receptor type 2 (HER2)-negative (HR+/HER2-)...
Main Authors: | Shunchao Yan, Murshid Imam |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer
2023-06-01
|
Series: | Discover Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1007/s12672-023-00732-0 |
Similar Items
-
BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy
by: Salar Farokhi Boroujeni, et al.
Published: (2023-11-01) -
Pancreatic Cancer: Beyond Brca Mutations
by: Vincenzo Ricci, et al.
Published: (2022-12-01) -
Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment
by: Chuanlin Wang, et al.
Published: (2022-12-01) -
ER-positive and BRCA2-mutated breast cancer: a literature review
by: Pu-Chun Li, et al.
Published: (2024-01-01) -
PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology
by: Federica Miglietta, et al.
Published: (2022-12-01)